Physician profile
Michael Arnstein
NPI 1821000100
$13,323.91
in general payments reported to CMS, 2019-2025
18 companies · $2,203 in 2025
The $2,203 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,179 · 2020: $317 · 2021: $1,769 · 2022: $1,611 · 2023: $2,015 · 2024: $4,230 · 2025: $2,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,010 · Travel and Lodging: $1,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,009.84 |
| Travel and Lodging | $1,437.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,410.58 | 2023-2025 | Natrelle Saline-Filled Breast Implants, Strattice Reconstructive Tissue Matrix Bps, Alloderm |
| Allergan, INC. | $2,981.53 | 2019-2022 | |
| Polynovo North America LLC | $1,612.97 | 2024-2025 | Novosorb Btm |
| Integra Lifesciences Corporation | $1,183.68 | 2019-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Urgo Medical North America, LLC | $1,077.45 | 2024-2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Urgoclean Ag |
| Sientra, INC. | $680.73 | 2019-2022 | |
| Smith+Nephew, INC. | $651.95 | 2019-2024 | Stravix Pl, Grafix, Stravix |
| Organogenesis INC. | $578.70 | 2022-2024 | Puraply, Apligraf |
| Biotissue Holdings INC. | $220.34 | 2022-2025 | |
| Access Pro Medical, LLC | $184.45 | 2025 | Matriderm |
| Kci USA, INC. | $160.28 | 2022-2023 | Prevena |
| Acera Surgical, INC. | $154.70 | 2025 | Restrata Wound Matrix |
| Stryker Corporation | $131.57 | 2021 | |
| Derma Sciences, INC. | $120.85 | 2019 | |
| Osiris Therapeutics INC. | $61.17 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acell, INC. | $50.16 | 2019 | |
| Janssen Biotech, INC. | $38.42 | 2023 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $24.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Arnstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.